Disease-associated antigens and methods of use thereof
AssigneeThe Regents of the University of California
InventorsLawrence H. Fong, Serena Kwek MacPhee
Life of this patent
Estimating the term…
Abstract
The present disclosure provides synthetic antibodies specific for a disease-associated antigen, and methods of using the antibodies in disease therapy. The present disclosure further provides diagnostic assays involving detecting the presence and/or level in biological sample of an antibody specific for a disease-associated antigen.
Claims26
A synthetic prostate cancer-associated polypeptide antigen, wherein the antigen comprises a polypeptide comprising an amino acid sequence having at least about 85% amino acid sequence identity to the amino acid sequence set forth in one of SEQ ID NOs:
- 1-42 and 108-147.
A method of determining the likelihood that an individual having prostate cancer will exhibit a clinically beneficial response to treatment with an immunomodulatory treatment regimen, the method comprising detecting in a biological sample obtained from the individual a level of antibody specific for one or more prostate cancer-associated antigens selected from a polypeptide of any one of SEQ ID NOs:
- 1-42 and 108-147, wherein a level of antibody that is at least about 25% higher than a control level of the antibody indicates that the individual is likely to exhibit a clinically beneficial response to the treatment.
A synthetic Systemic Lupus Erythematosus (SLE)-associated polypeptide antigen, wherein the antigen comprises a polypeptide comprising an amino acid sequence having at least about 85% amino acid sequence identity to the amino acid sequence set forth in one of SEQ ID NOs:
- 43-85, 148, and 149.
A method of diagnosing an individual as having Systemic Lupus Erythematosus (SLE), the method comprising detecting in a biological sample obtained from the individual a level of antibody specific for an SLE-associated polypeptide antigen selected from a polypeptide of any one of SEQ ID NOs:
- 43-85, 148, and 149, wherein a level of antibody greater than a level of antibody specific for the SLE-associated polypeptide antigen from a control individual is indicative of SLE.
A method of assessing whether an individual is at risk of developing Systemic Lupus Erythematosus (SLE), the method comprising detecting in a biological sample obtained from the individual a level of antibody specific for an SLE-associated polypeptide antigen selected from a polypeptide of any one of SEQ ID NOs:
- 43-85, 148, and 149, wherein a level of antibody greater than a level of antibody specific for the SLE-associated polypeptide antigen from a control individual indicates that the individual is at risk for developing type 1 insulin dependent diabetes mellitus.
A synthetic type 1 insulin dependent diabetes mellitus-associated polypeptide antigen, wherein the antigen comprises a polypeptide comprising an amino acid sequence having at least about 85% amino acid sequence identity to the amino acid sequence set forth in one of SEQ ID NOs:
- 86-107 and 150-155.
A method of diagnosing an individual as having type 1 insulin dependent diabetes mellitus, the method comprising detecting in a biological sample obtained from the individual a level of antibody specific for a type 1 diabetes-associated polypeptide antigen selected from a polypeptide of any one of SEQ ID NOs:
- 86-107 and 150-155, wherein a level of antibody greater than a level of antibody specific for the type 1 diabetes-associated polypeptide antigen from a control individual is indicative of type 1 insulin dependent diabetes mellitus.
A method of assessing whether an individual is at risk of developing type 1 insulin dependent diabetes mellitus, the method comprising detecting in a biological sample obtained from the individual a level of antibody specific for a type 1 diabetes-associated polypeptide antigen selected from a polypeptide of any one of SEQ ID NOs:
- 86-107 and 150-155, wherein a level of antibody greater than a level of antibody specific for the type 1 diabetes-associated polypeptide antigen from a control individual indicates that the individual is at risk for developing type 1 insulin dependent diabetes mellitus.
Dependencies are inferred from the claim text.